May. 12 at 3:14 PM
$ATOS The perceived lack of focus from Dr. Steven Quay stems from his frequent public commentary on topics ranging from COVID-19 origins and Ivermectin to current health scares like Hantavirus. This extracurricular activity often overshadows the core mission of Atossa Therapeutics (
$ATOS), leading to investor frustration that he is prioritizing personal branding and public health punditry over the commercialization of (Z)-endoxifen.
Someone needs to tell him that is not acceptable.
